AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03351829 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Gene-modified autologous stem cells
Description: 1 infusion for 5x10\^6\~1x10\^7 gene-modified cells; or more infusions depending on the circumstances
Study NCT00577629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 1.5g/m2 IV over 1 hour on days 1-4 of induction for a total dose of 6.0g/m2
Study NCT00577629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 300mg/m2 IV over 1 hour every 12 on days 1-3 of induction for a total dose of 1.8 g/m2.
Study NCT00577629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375mg/m2 each week x 4 weeks of induction, beginning on day 1
Study NCT00577629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 3g/m2 IV over 1 hour every 12 during consolidation for a total of 8 doses
Study NCT05419908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Oral Capsule
Study NCT05419908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study NCT00577629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 45mg/m2/day IV over 30 minutes on days 1, 2, 3 during consolidation
Study NCT03615131 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI-TRUS fusion prostate biopsy
Description: First an advanced MRI prostate image is obtained, annotated and recorded by the Radiology of the Kantonsspital Winterthur. Next, using special fusion technology, the recorded MRI image is fused with a live transrectal ultrasound by the Urologist who performs a MRI/TRUS fusion biopsy.
Study NCT00273780 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adherence counseling
Description: Three adherence counseling sessions will be given to participants in the trial. Two sessions will occur prior to initiation of antiretroviral medications and one session will be given one month after drug administration.
Study NCT00273780 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alarm device
Description: This pocket alarm device will be set to ring at designated times during the day that the participant should take their antiretroviral medication.
Study NCT01931826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic treatment
Description: The presence of gastroesophageal varices was confirmed by fiberoptic esophagogastroduodenoscopy (EGD). In view of the experience of our service and local circumstances at the time of the study, the endoscopic treatment of choice was sclerotherapy, performed with a Teflon-sheathed metal needle. The sclerosing agent was 2.5% monoethanolamine oleate. Esophageal varices visible on EGD in the pre- and post-treatment period were classified as small, medium or large on the basis of criteria proposed by Paquet. All complications attributable to sclerotherapy were recorded.
Study NCT01931826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total EGDS+ endoscopy
Description: Esophagogastric devascularization with splenectomy followed by endoscopic sclerotherapy of esophageal varices 2 months postoperatively.
Study NCT00577629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tositumomab
Description: 450mg unlabeled tositumomab over 1 hour, followed by 5 millicurie (mCi) Iodine I-131 labeled tositumomab over 20 minutes on day 0. Therapeutic dose of labeled tositumomab will be administered on day 15.
Study NCT03771326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kisspeptin-10
Description: Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)
Study NCT03912103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interdisciplinary Deprescribing and Medication Optimization Intervention
Description: as current
Study NCT04187534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Albumin Fluid Resuscitation Optimization Intervention
Description: Multi-faceted quality improvement intervention to optimize appropriateness of albumin use for fluid resuscitation
Study NCT04187534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Practice
Description: Albumin fluid resuscitation according to usual practice
Study NCT04293991 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannula
Description: Evaluate the use of HFNC in prevention of intubation in immunocompromised patients adimitted to icu.
Study NCT04293991 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non Invasive Ventilation
Description: Evaluate the use of HFNC in prevention of intubation in immunocompromised patient admitted to icu.
Study NCT03017456 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survivorship Care Plan
Description: SCP-Intervention: Patients in the SCP-Int arm will attend a one-time appointment with a trained oncology nurse while the patients in the UC arm will receive care according to the hospital standards for follow-up care. The intervention will be delivered during a regular follow-up appointment, face-to-face and will inform and educate patients on self-management and support as well as promote access to and coordination of post-treatment care. The appointment will focus on empowering the PC survivor to actively self-manage persistent treatment effects and to decrease their risk of late effects by providing effective health information, support, and self-management support. Nurses will integrate a number of active behavior change ingredients including the integration of motivational interviewing techniques which are effective in increasing healthy behaviors.
Study NCT00052962 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cytoreductive surgery
Description: Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.~Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m\^2 on day 1 only, leucovorin 200 mg/M\^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m\^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}.
Study NCT01065805 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 18F-FLT
Description: Phase I: Radioactive dose of 2.59 MBq/kg (111-222 MGq)per injection. A single injection of 18F-FLT and PET scan will be permitted per patient.~Phase II: Radioactive dose of 2.59 MBq/kg (100-350) MBq per injection. Up to five separate injections of 18F-FLT and PET scans will be permitted per patient
Study NCT03307057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Communication Growth Charts (SCGC)
Description: The Social Communication Growth Charts (SCGC) is a web-based tool that parents can access to teach them the social communication milestones that are developing from 6 to 24 months of age. The SCGC has an explore function with hundreds of video clips illustrating 80 social communication milestones and a support video that has narration explaining how the parent in the video is supporting the child's development. The SCGC also has a charting function that parents can use by answering questions about their child's social communication milestones and then view charts in 5 developmental domains. Parents in the SCGC condition are also invited to a bi-weekly online Guided Tour to join other parents in a group meeting, like a book club, as they go through the SCGC.
Study NCT03307057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Implemented (P-I) Condition
Description: The Parent-Implemented (P-I) condition is based on the Early Social Interaction (ESI) model, which is an evidence-based parent-implemented intervention involving active and productive engagement for 5 hours per day, 5 days per week for toddlers with ASD. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places.~Weekly home sessions with a family navigator include:~1. developing the visit agenda~2. intervention implementation including: guided/caregiver practice, feedback and problem solving~3. planning for parent implementation between sessions~Families can also access the Autism Navigator How-To Guide for Families (a self-guided, web-based course), the Online Guided Tour for the How-To Guide (an online group to engage families), and have the opportunity to interact with other families who suspect their child has autism through audio or video conferencing or typed chat.
Study NCT03307057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician-Implemented (C-I) Condition
Description: The Clinician-Implemented (C-I) condition is based on the core principles of empirically-supported naturalistic developmental behavioral interventions (NDBI) for infants and toddlers with or at-risk for ASD, including Early Start Denver Model (ESDM), Project ImPACT (Improving Parents As Communication Teachers), Pivotal Response Treatment (PRT), and Early Social Interaction (ESI). The goal of C-I NDBI is to use naturalistic, developmental, and behavioral strategies with infants at-risk for ASD to improve social-communication, which includes eye contact, gesture use, intentional vocalizations, and language. Parents are not actively involved in C-I NDBI intervention sessions, though they may observe and the clinician will be given information about current social-communication targets.
Study NCT03307057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Care as recommended and provided by the child's pediatrician or other health care providers in the community.
Study NCT03307057 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Care as recommended and provided by the child's pediatrician or other health care providers in the community.
Study NCT06709326 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Apheresis
Description: Isolate tumor cells, immune cells, exosomes and cell free DNA from the blood by a clinically used method of whole blood volume filtration, apheresis, and subsequent separation of blood components using novel techniques, such as acoustophoresis and other experimental protocols.
Study NCT06709326 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: Isolate tumor cells, immune cells, exosomes and cell free DNA from the blood by a clinically used method of whole blood volume filtration, apheresis, and subsequent separation of blood components using novel techniques, such as acoustophoresis and other experimental protocols.
Study NCT06709326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Description: Apheresis will be performed before initiation of systemic therapy (androgen deprivation therapy) and 4 weeks after. Androgen deprivation therapy is treatment as per clinical routine and not part of the protocol.
Study NCT06709326 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anti androgen therapy
Description: Apheresis will be performed before initiation of systemic therapy (anti androgen therapy). Anti androgen therapy is treatment as per clinical routine and not part of the protocol.
Study NCT00918398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: 100 mg iv infusion, single dose, 4 hours infusion
Study NCT00052962 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Continuous hyperthermic peritoneal perfusion (HIPEC/CHPP)
Description: Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.~Followed by continuous hyperthermic peritoneal perfusion (HIPEC) with 250 mg/m\^2 cisplatin. Post operative dwell chemotherapy given once between post op day 7 and 12: 5-fluororacil (5-FU) 800 mg/m\^2 and paclitaxel 125 mg/m\^2.~Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m\^2 on day 1 only, leucovorin 200 mg/M\^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m\^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}.
Study NCT01941069 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping Power Program
Description: The Coping Power Program CPP is a cognitive-behavioral, multi-component group intervention for elementary and middle school students at risk for externalizing behavior disorders. In addition to anger management, the CPP includes units on goal setting, emotional awareness, relaxation training, social skills training, problem solving, and handling peer pressure.
Study NCT03555136 — intervention group
Intervention type: DRUG
Intervention: Vortioxetine
Description: Treatment with vortioxetine as per local SmPC
Study NCT03372317 — intervention group
Intervention type: DRUG
Intervention: 18F-MK-6240
Description: Results of the 18F-MK-6240 PET scan will be correlated with other observations.
Study NCT01937689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib either at 80, 160, 240, 320, 400, 480 mg ....., p.o. once daily.
Study NCT02377349 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Boostrix™
Description: One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
Study NCT02377349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix™
Description: One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
Study NCT02377349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
Study NCT02152865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lupeol
Description: Patients are supposed to apply lupeol cream to one side of their face two times per day for 8 weeks.
Study NCT02152865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control vehicle
Description: Patients are supposed to apply their control vehicle to the other side of their face for 8 weeks
Study NCT01818622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue-blocking goggles/screens
Description: Goggles with amber tinted lenses, all model's transmittance spectra are identical. Goggles and screens are tested at Department of Physics and Technology, University of Bergen. Patients and non-bipolar controls choose model for best comfort.
Study NCT01818622 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Clear-lensed goggles
Description: Clear lensed safety eyewear. Patients may choose model for best comfort.
Study NCT00112151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LowT
Description: Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
Study NCT00112151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Weight training 45-60 minutes 3 times per week
Study NCT02377349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
Study NCT02361736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl Starch
Description: 6% Hydroxyethyl Starch(HES) is intravenously given 7.5ml/kg for the first hour of surgery
Study NCT02361736 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lactate Ringers
Description: Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
Study NCT04531527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butenafine HCl 1% (BAY1896425)
Description: Approximately 60 μl of Butenafine HCl 1% applied twice to the treated irradiated site and to the treated non-irradiated site for a total application of 240 μl of Butenafine HCl 1%.
Study NCT03177187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: 10mg and 40mg plain, beige, film-coated tablets packaged in bottles
Study NCT02093962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302 combination with pemetrexed
Description: 400 mg/m2 of TH-302 will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after TH-302 administration.
Study NCT02093962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matched placebo in combination with pemetrexed
Description: Matched placebo will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after placebo administration.
Study NCT04621045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Physical Activity for The Heart (PATH) intervention
Description: The web-based Physical Activity for The Heart (PATH) intervention leverages openly accessible platforms, such as YouTube, to proffer workout videos that match the participants preferences. Currently, PATH includes over 90 workout videos vetted by a team of experts and curated on the PATH website in 3 controlled levels of intensity (beginner, intermediate, proficient) to foster gradual progression from low to high intensity PA in accordance with the FITT-VP (frequency, intensity, time, type, volume, progression) principle.
Study NCT04621045 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Be Active Your Way Booklet
Description: Be Active Your Way booklet was developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives. It simply encourages individuals to increase their PA gradually and gives them examples of things that they can do.
Study NCT01956162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthèse Diabète
Description: The device ensures the discharge of the wound by the excavation of the orthopedic insole facing the wound and the load distribution in the healthy areas.
Study NCT01956162 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Device
Description: Standard (e.g.: CHUT, BAROUK, Tera-Diab, Sanital, Teraheel, Aircast boots, Walker Stabil D, etc.), or customized (orthopedic insole, Ransart boot, D.T.A.C.P., etc.) removable off-loading systems
Study NCT06708247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Peri-implant Reconstructive Surgery
Description: This intervention involves standard peri-implant reconstructive surgery without the additional step of electrolytic cleaning. The procedure includes mechanical debridement of the implant surface to remove biofilm, followed by bone grafting using autogenous bone harvested from the tuberosity and coverage with a resorbable collagen membrane for bone regeneration and stabilization of the implant.
Study NCT03177187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide 40 MG
Description: Enzalutamide is presented in 40mg white to off white capsules or tablets. The capsules/tablets are provided in a cardboard wallet incorporating a PVC/PCTFE/aluminium blister which holds 28 soft capsules/tablets. Each carton contains 4 wallets (112 soft capsules/tablets). Or tablets in bottles (120 per bottle).
Study NCT06708247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrolytic Cleaning with Peri-implant Reconstructive Surgery
Description: This intervention involves peri-implant reconstructive surgery with an added step of electrolytic cleaning for enhanced implant surface decontamination. The procedure starts with mechanical debridement of the implant surface, followed by the use of an electrolytic cleaning device to remove biofilm and contaminants without damaging the implant surface. This is then followed by bone grafting using autogenous tuberosity bone and coverage with a resorbable collagen membrane to promote bone regeneration and implant stability.
Study NCT00112151 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: Weight training 45-60 minutes 3 times per week
Study NCT00112151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2.5 gm gel packets applied once daily. Sham adjustments made during the first 12 weeks. Duration is 52 weeks.
Study NCT06709937 — intervention group
Intervention type: OTHER
Intervention: Prospective multicenter registry of patients with cutaneous metastases from breast carcinoma treated with electrochemotherapy.
Description: electrochemotherapy.
Study NCT02513914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dural Venous Sinus Stenting
Description: See Dural Venous Sinus Stenting arm.
Study NCT02513914 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebrospinal Fluid Shunting
Description: See Cerebrospinal Fluid Shunting arm.
Study NCT02862418 — intervention group
Intervention type: OTHER
Intervention: UTE MRI
Description: One MRI with UTE settings will be acquired.
Study NCT03480971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tempol
Description: Investigational product is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) oral solution. Tempol solution is an orange-colored, aqueous solution containing 7% Tempol along with xanthan gum, xylitol, aspartame, acesulfame potassium, sodium saccharin, alcohol, peppermint and wintergreen oils.
Study NCT03480971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Solution
Description: The placebo contains the same excipients as the active product plus FD\&C Yellow #6 for color matching.
Study NCT00112151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2.5 gm gel packets applied once daily. Sham adjustments made during the first 12 weeks. Duration is 52 weeks.